Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.

Caitlin M O'Connor Sarah E Taylor Kathryn M Miller Lauren Hurst Terrance J Haanen Tahra K SuhanKaitlin P ZawackiFallon K NotoJonida TrakoArathi MohanJaya SangodkarDmitriy Zamarin Analisa DiFeoGoutham Narla

Published in: Cancer research (2022)

A drug repurposing screen identifies synthetic lethal interactions in PP2A-deficient uterine serous carcinoma, providing potential therapeutic avenues for treating this deadly endometrial cancer.

Keyphrases

endometrial cancer
high grade
genome wide
emergency department
adverse drug
single cell
electronic health record